🔍

ACUTAAS - Acutaas Chemical

📊 NSE: ACUTAAS 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Acutaas Chemicals to Attend Investec India Investor Conference on March 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 12:01 PM

Acutaas Chemicals Limited has announced its participation in the Investec India Promoter & Founder Conference 2026. The event is scheduled for March 11, 2026, in Mumbai, where company officials will engage in one-on-one and group meetings with institutional investors and analysts. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be discussed during these interactions. This meeting is part of the company's regular investor relations engagement following its name change from Ami Organics Limited.

Participation in Investec India Promoter & Founder Conference 2026 scheduled for March 11, 2026.
Interaction format includes both one-on-one and group meetings with analysts and investors.
Physical attendance by company officials confirmed for the Mumbai-based event.
Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015.
Management confirmed that no unpublished price-sensitive information will be shared.

💡 Investors should monitor for any investor presentations or meeting transcripts released after the conference for updates on the company's strategic direction. No immediate action is required as this is a routine disclosure of investor engagement.

Acutaas Chemicals to Attend Investor Conferences with Ombkara Capital and Kotak in February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 12:31 PM

Acutaas Chemicals Limited (formerly Ami Organics Limited) has announced its participation in two upcoming investor conferences in Mumbai. The company is scheduled to meet with Ombkara Capital on February 21, 2026, followed by the Kotak Flagship Conference 'Chasing Growth 2026' on February 24, 2026. These interactions will include both one-on-one and group meetings with institutional investors and analysts. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be discussed during these sessions.

Participation in Ombkara Capital Investors Meet scheduled for February 21, 2026.
Attendance at the Kotak Flagship Conference — Chasing Growth 2026 on February 24, 2026.
Meetings will be held in Mumbai and feature one-on-one and group interaction formats.
Management confirmed that no unpublished price-sensitive information will be shared during the meets.

💡 Investors should look for any investor presentations or transcripts that may be uploaded to the exchanges following these meetings for insights into the company's growth outlook. No immediate trading action is required as this is a routine investor relations activity.

Acutaas Chemicals Completes 75% Acquisition of South Korean Semiconductor Chemical Firm Indichem

🟢 POSITIVE ⭐ 8/10

M&A 📅 11 Feb 2026, 07:01 PM

Acutaas Chemicals, through its wholly owned subsidiary Acutaas Advance Material Limited, has completed the acquisition of a 75% controlling stake in South Korean firm Indichem Inc. Indichem is a newly incorporated entity specializing in the semiconductor chemicals industry, providing Acutaas with a strategic entry into this high-growth global market. The acquisition involved 300,000 shares at a par value of KRW 500 each plus a share premium. Indichem is currently constructing a manufacturing plant in South Korea, which is scheduled for commissioning by the end of the 2025 calendar year.

Acquired 75% controlling stake (300,000 shares) in South Korean firm Indichem Inc.
Target entity operates in the specialized semiconductor chemicals industry.
Acquisition price set at KRW 500 per share par value plus applicable share premium.
Manufacturing plant in South Korea is slated for commissioning by the end of 2025.
Indichem Inc. now becomes a step-down subsidiary of Acutaas Chemicals Limited.

💡 This acquisition is a strategic move into the high-margin semiconductor value chain. Investors should monitor the timely commissioning of the South Korean facility by late 2025 as it will be the primary driver for revenue from this new segment.

Acutaas Chemicals Q3 FY26 PAT Jumps 133.7% to ₹106.2 Cr; Revenue Guidance Raised to 30%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 03 Feb 2026, 02:54 PM

Acutaas Chemicals reported a stellar Q3 FY26 with revenue growing 43% YoY to ₹393.2 crores, driven by a 47% surge in the Advanced Pharma Intermediates segment. The company achieved its highest-ever margins, with EBITDA margins expanding significantly to 38.3% due to a favorable product mix and operating leverage. Management has upgraded its full-year FY26 revenue growth guidance to 30% and EBITDA margin guidance to a range of 32-35%. Strategic expansions into battery and semiconductor chemicals are progressing, with a new battery chemicals block inaugurated in January 2026.

Revenue from operations grew 43% YoY to ₹393.2 crores in Q3 FY26.
PAT crossed the ₹100 crore milestone, reaching ₹106.2 crores, a 133.7% YoY increase.
EBITDA margins expanded by 1,335 bps YoY to 38.3%, leading to an upgraded annual margin guidance of 32-35%.
Pharma Intermediates segment revenue rose 47% YoY to ₹351.1 crores, fueled by CDMO growth.
Inaugurated a new battery chemicals block at Jhagadia; commercial operations expected to ramp up from Q1 FY27.

💡 Investors should view the guidance upgrade and margin expansion as strong indicators of structural growth and improved product mix. The entry into high-growth battery and semiconductor chemical segments provides a long-term catalyst for valuation re-rating.

Acutaas Chemicals Reports FY25 Revenue of ₹9,898 Million and 25% Capacity Expansion

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 29 Jan 2026, 06:29 PM

Acutaas Chemicals Limited, formerly known as Ami Organics, has released its Annual Sustainability Report for FY 2024-25, reporting a standalone revenue of ₹9,898 million. The company achieved a significant 25% increase in production capacity, primarily driven by its Ankleshwar facility. Strategically, the firm is expanding into high-value sectors including semiconductor-grade chemistries and battery materials. On the ESG front, it earned the EcoVadis Platinum Medal, placing it in the top 1% of companies globally, and operationalized 15.8 MW of solar capacity.

Standalone revenue reached ₹9,898 million with consolidated revenue surpassing ₹1,000 crore
Production capacity increased by 25% during the fiscal year, led by the Ankleshwar unit
Achieved EcoVadis Platinum Medal and operationalized 15.8 MW of solar power capacity
Portfolio expanded to over 610 chemistries with exports to more than 55 countries
Zero conflict-of-interest cases and zero POSH complaints reported for the year

💡 Investors should note the company's successful transition to its new identity and its strong ESG positioning which may attract institutional capital. The 25% capacity expansion and move into semiconductor chemicals provide a positive outlook for medium-term growth.

Acutaas Chemicals Q3 FY26 Net Profit Surges 139% YoY to ₹108.6 Cr; Revenue Up 42%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 05:45 PM

Acutaas Chemicals (formerly Ami Organics) reported a stellar performance for Q3 FY26, with consolidated revenue growing 42.3% YoY to ₹391.2 crore. Net profit for the quarter witnessed a massive jump of 139% YoY, reaching ₹108.6 crore compared to ₹45.4 crore in the previous year. For the nine-month period, the company has already surpassed its full-year FY25 profit, recording ₹222.1 crore. The company also highlighted a strategic investment of ₹130.80 crore in its South Korean joint venture, Indichem Inc., to bolster its specialty chemicals portfolio.

Consolidated Revenue from operations rose 42.3% YoY to ₹39,118.33 Lakhs in Q3 FY26.
Net Profit surged by 139% YoY to ₹10,863.62 Lakhs, driven by strong operational efficiency.
Basic EPS for the quarter stood at ₹13.12, up from ₹5.42 in the corresponding quarter of the previous year.
The company invested ₹130.80 crore in South Korean JV Indichem Inc., holding a 75% stake through its subsidiary.
9-month consolidated profit reached ₹22,208.56 Lakhs, a 127% increase over the ₹9,770.16 Lakhs recorded in 9M FY25.

💡 The company is exhibiting robust earnings momentum and successful execution of its global expansion strategy. Investors should maintain a positive outlook while monitoring the integration of the South Korean JV and the impact of the newly granted ESOPs on future employee costs.

Acutaas Chemicals Releases Audio Recording of Earnings Call Held on January 28, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 28 Jan 2026, 06:33 PM

Acutaas Chemicals Limited has officially released the audio recording of its earnings conference call conducted on January 28, 2026. The disclosure is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following the company's initial notification on January 22, 2026. The recording provides transparency regarding management's discussion on the company's financial performance and strategic outlook. Investors can access the full audio file via the company's investor relations website.

Earnings call was held on January 28, 2026, at 5:00 p.m. IST.
Recording link is available on the company website as per SEBI Regulation 30 and 46(2).
The filing follows a prior intimation regarding the call submitted on January 22, 2026.
The audio file is hosted at https://acutaas.com/static/uploadfiles/downloads/download_5812.mp3.

💡 Investors should listen to the recording to understand management's perspective on quarterly results and future growth guidance. This is a routine administrative filing and does not necessitate immediate portfolio changes.

Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Up 43%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 28 Jan 2026, 03:11 PM

Acutaas Chemicals reported a stellar performance for Q3 FY26, with revenue growing 43% YoY to ₹3,932 million. The company achieved a significant milestone as quarterly PAT crossed ₹1,000 million for the first time, reaching ₹1,062 million. Profitability margins saw substantial expansion, with EBITDA margins jumping to 38.3% from 25.0% in the previous year. Management has also raised its full-year revenue growth guidance from 25% to approximately 30%, citing strong momentum in the CDMO business and upcoming verticals like battery and semiconductor chemicals.

Revenue from operations grew 43% YoY to ₹3,932 million, driven by the CDMO business ramp-up.
Net Profit (PAT) skyrocketed by 133.7% YoY to ₹1,062 million, crossing the ₹1,000 million quarterly milestone.
EBITDA margins expanded significantly by 1,330 bps YoY to reach 38.3% compared to 25.0% in Q3FY25.
Full-year revenue growth guidance revised upward from 25% to approximately 30% for FY26.
Gross margins improved to 57.0%, up 1,073 bps YoY, reflecting a superior product mix and operational efficiency.

💡 Investors should take note of the significant margin expansion and the management's confidence reflected in the upward guidance revision. The company's strategic pivot into semiconductor and battery chemicals offers strong long-term growth catalysts beyond its core pharmaceutical business.

Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Guidance Raised to 30%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 03:04 PM

Acutaas Chemicals reported a stellar Q3 FY26 performance with revenue growing 43% YoY to ₹3,932 million, driven by a robust ramp-up in the CDMO business. Profitability saw a massive jump as EBITDA rose 119.4% to ₹1,507 million, with margins expanding significantly to 38.3% due to favorable product mix and operating leverage. Consequently, PAT grew by 133.7% YoY to reach ₹1,062 million, the highest ever for the company. Management has revised its full-year revenue growth guidance upward to approximately 30% based on a strong order book and improved visibility.

Revenue from operations grew 43% YoY to ₹3,932 million in Q3 FY26.
EBITDA margins expanded by 1,330 bps YoY to 38.3%, leading to EBITDA of ₹1,507 million.
Net Profit (PAT) increased by 133.7% YoY to ₹1,062 million with a 27% margin.
Management raised FY26 revenue growth guidance from 25% to approximately 30%.
Advanced Intermediates segment remains the primary driver, contributing ₹3,511 million to revenue.

💡 Investors should view the significant margin expansion and guidance upgrade as a strong bullish signal. The company's strategic pivot into high-growth battery and semiconductor chemicals provides a long-term growth runway.

Acutaas Chemicals Reports Q3 FY26 Results; Auditor Issues Clean Review Report

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 28 Jan 2026, 02:49 PM

Acutaas Chemicals Limited, formerly known as Ami Organics Limited, has submitted its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The independent auditor, Maheshwari & Co., has issued a clean review report, indicating no material misstatements in the financial statements. The consolidated results encompass various subsidiaries including Acutaas Chemicals Electrolytes and Acutaas Advance Material, as well as joint ventures. This filing confirms the company's adherence to SEBI's regulatory reporting requirements.

Acutaas Chemicals (formerly Ami Organics) filed financial results for the period ended December 31, 2025.
Independent Auditor Maheshwari & Co. issued an unmodified review report for both standalone and consolidated financials.
The consolidated entity includes subsidiaries such as Baba Fine Chemicals and step-down subsidiaries like Indichem Inc.
Financial statements were prepared in accordance with Ind AS 34 (Interim Financial Reporting) and SEBI Regulation 33.
The board meeting for the approval of these results was concluded on January 28, 2026.

💡 Investors should review the detailed profit and loss statements once fully published to assess revenue and margin performance. The clean audit report provides confidence in the company's financial reporting integrity.

Acutaas Chemicals Receives Relief as GST Demand of Rs 15.44 Lakhs is Dropped

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 27 Jan 2026, 06:19 PM

Acutaas Chemicals Limited has received a favorable order from the GST Appeals Commissionerate in Surat regarding a previously contested tax matter. The authority has dropped a demand for ineligible Input Tax Credit (ITC) amounting to Rs. 15.44 lakhs. This decision also waives the associated interest and an equal amount of penalty that was previously levied against the company. The resolution of this pending litigation removes a potential financial liability and administrative burden.

GST demand of Rs. 15.44 lakhs regarding ineligible Input Tax Credit (ITC) has been officially dropped
The order waives interest and an equal penalty amount previously associated with the claim
Order passed by the Office of the Additional Commissioner, Central GST & Central Excise (Appeals), Surat
Company confirms no further financial or operational impact following this resolution

💡 This is a minor positive development as it clears a pending tax dispute. Investors should continue to focus on the company's core chemical business performance and operational growth.

Acutaas Chemicals Schedules Q3FY26 Earnings Conference Call for January 28, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 22 Jan 2026, 07:17 PM

Acutaas Chemicals Limited, formerly known as Ami Organics Limited, has scheduled its earnings conference call for Wednesday, January 28, 2026, at 5:00 PM IST. The management will discuss the company's financial performance for the third quarter and nine months ended December 31, 2025. Key participants include Chairman and MD Mr. Naresh Patel and CFO Mr. Bhavin Shah. This call provides a platform for institutional investors and analysts to gain insights into the company's operational trajectory following its recent rebranding.

Earnings conference call scheduled for January 28, 2026, at 5:00 PM IST.
Focus on financial results for Q3 and the nine-month period ending December 31, 2025.
Top management including the Chairman, MD, and CFO will be present for the discussion.
The call is being hosted by JM Financial Institutional Securities Limited.
Universal dial-in numbers provided are +91-22-6280 1366 and +91-22-7115 8267.

💡 Investors should attend or review the transcript of the call to understand management's outlook on the chemical sector and any strategic shifts following the name change. Key metrics to watch include margin sustainability and revenue growth for the nine-month period.

Acutaas Chemicals Inaugurates Phase 1 Battery Chemicals Block at Jhagadia Facility

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 19 Jan 2026, 02:31 PM

Acutaas Chemicals Limited has officially inaugurated Phase 1 of its new state-of-the-art manufacturing block at the Unit-III Jhagadia facility in Gujarat. This dedicated facility will focus on producing electrolyte additives and other battery chemicals, marking a significant expansion into the high-growth EV supply chain. The inauguration took place on January 19, 2026, following an initial project intimation in December 2024. This move aligns with the company's strategy to diversify its specialty chemical portfolio into the energy storage sector.

Inauguration of Phase 1 of a dedicated manufacturing block for electrolyte additives and battery chemicals.
The facility is located at the existing Unit-III Jhagadia site at Plot No. 910/1/B, G.I.D.C., Gujarat.
The expansion follows through on the company's strategic plan initiated on December 11, 2024.
The new block is described as a 'State of the Art' facility targeting the specialized battery materials market.

💡 Investors should view this as a positive development for long-term growth in the specialty chemicals space. Monitor the ramp-up of production and the subsequent impact on revenue and margins in the upcoming fiscal quarters.

Acutaas Chemicals Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 04:19 PM

Acutaas Chemicals Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by Registrar MUFG Intime India Private Limited, covers the quarter ended December 31, 2025. It confirms that the company received zero requests for the dematerialization of securities during this period. This is a standard regulatory filing ensuring the integrity of the share register and depository records.

Compliance certificate submitted for the quarter ended December 31, 2025
Registrar MUFG Intime India confirmed zero dematerialization requests were received
No security certificates were mutilated or cancelled during the reporting period
No changes were required in the register of members regarding depository ownership

💡 No action is required as this is a routine administrative filing. Investors should continue to monitor the company's operational performance and upcoming financial results.

Acutaas Chemicals to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 12:13 PM

Acutaas Chemicals Limited has announced the closure of its trading window effective from January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is for the purpose of considering the unaudited financial results for the third quarter ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are declared. The specific date for the board meeting to approve these results will be communicated in due course.

Trading window closure begins on Thursday, January 1, 2026
Closure is for the consideration of unaudited financial results for Q3 ending December 31, 2025
Window to reopen 48 hours after the official declaration of financial results
Applicable to all Designated Persons and their immediate relatives as per the Company's Code of Conduct

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should monitor for the upcoming announcement of the board meeting date to review the company's Q3 performance.

View All ACUTAAS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The Pharmaceutical Intermediates segment grew 50% YoY to INR 854 Cr in FY25, while the Specialty Chemicals segment grew 2.2% YoY to INR 152.9 Cr. Total revenue for Q2 FY26 reached INR 306.2 Cr, representing a 24.1% YoY growth, and H1 FY26 revenue reached INR 513.4 Cr, a 21% increase.

Geographic Revenue Split

In FY25, exports accounted for 74% of total revenue, while the domestic business contributed 26%. The company has a widespread geographical presence across more than 55 countries.

Profitability Margins

Gross margin for Q2 FY26 was 55.8%, an expansion of 1,232 basis points YoY. PAT margin for Q2 FY26 was 23.5%, expanding by 824 basis points. FY25 PBILDT margin was 23.51%, up from 18.39% in FY24, driven by a shift in sales mix toward higher-margin products.

EBITDA Margin

EBITDA margin for Q2 FY26 was 31.1%, up 1,130 basis points YoY. The company has provided a guidance of 28% to 30% for FY26, driven by higher CDMO contribution and operational efficiencies.

Capital Expenditure

Gross Cash Accruals (GCA) doubled to INR 193.59 Cr in FY25 from INR 100.70 Cr in FY24, supporting internal funding of projects. Block 3 was commissioned in Q4 FY24 and is now operational to meet customer requirements.

Credit Rating & Borrowing

The company holds a CARE A+; Stable / CARE A1+ rating as of December 2025. Interest coverage is exceptionally strong at 119.86x for H1 FY26, with an overall gearing ratio of 0.01x as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Key Starting Materials (KSM) and specific chemicals like VC and FEC for the electrolyte business; raw material costs represent approximately 72% of the total cost of sales.

Import Sources

Approximately 71% of raw materials are sourced domestically from India, while 21% are imported from China to ensure supply chain resilience.

Capacity Expansion

Block 3 was commissioned in Q4 FY24 for dedicated contracts. The company also operates a 6MW captive solar plant to drive energy efficiency. Electrolyte additive commercial operations have commenced with a ramp-up expected from FY26.

Raw Material Costs

Raw material costs account for 72% of total cost of sales. The company manages volatility by revising export prices quarterly based on KSM prices and using spot pricing for domestic sales.

Manufacturing Efficiency

The company is transitioning to Flow Chemistry to reduce solvent consumption and improve input-output efficiency. Operating leverage contributed to the 1,130 bps expansion in EBITDA margins in Q2 FY26.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

Growth will be achieved through the ramp-up of the CDMO business, which saw sharp growth in Q2 FY26, and the commercialization of semiconductor chemicals through Baba Fine Chemicals. The company is also churning out low-margin products from its core pharma portfolio to improve margins while maintaining a 25% revenue growth target. New verticals like electrolyte additives are expected to contribute significantly from FY26 onwards.

Products & Services

Advanced pharmaceutical intermediates for regulated and generic APIs, New Chemical Entities (NCE), photo-resistant specialty chemicals, and electrolyte additives for batteries.

Brand Portfolio

Acutaas Chemicals (formerly Ami Organics), Baba Fine Chemicals, Indichem (Korea), and Acutaas Advance Material Limited.

New Products/Services

Semiconductor chemicals and electrolyte additives for batteries; electrolyte business has firm orders in hand for FY26 ramp-up.

Market Expansion

Expanding Baba Fine Chemicals into new geographies and diversifying the international footprint across 55+ countries to mitigate regional economic slowdowns.

Strategic Alliances

Acquisition of a non-controlling stake in Indichem (Korea) and the acquisition of Baba Fine Chemicals (now Acutaas Advance Material Limited).

🌍 External Factors

Industry Trends

The specialty chemicals industry is evolving toward sustainable processes like Flow Chemistry. Acutaas is positioning itself as a diversified player across pharma, semiconductors, and battery chemicals to capture a 31% historical CAGR trend.

Competitive Landscape

Faces intensifying competition in specialty chemicals which can affect pricing; responds through product differentiation and cost leadership.

Competitive Moat

Moat is built on R&D capabilities, a portfolio of 610+ products, and high switching costs for customers in the regulated pharma space. This is sustainable due to the long-term nature of CDMO contracts and stringent regulatory approvals.

Macro Economic Sensitivity

Sensitive to global pharmaceutical demand and semiconductor industry cycles; revenue is highly dependent on the 74% export market.

Consumer Behavior

Shift toward energy-efficient and environmentally friendly chemical processes is driving the adoption of Flow Chemistry.

Geopolitical Risks

Ongoing tensions could disrupt the 21% of raw materials sourced from China or impact the 74% export revenue across 55 countries.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to strict regulatory standards for pharmaceutical intermediates and EHS protocols. Non-compliance could lead to operational disruptions.

Environmental Compliance

The company must adhere to stringent EHS regulations; it has invested in a 6MW solar plant and Flow Chemistry to meet environmental standards.

Taxation Policy Impact

Current tax provision for FY25 was INR 49.19 Cr on a consolidated basis.

⚠️ Risk Analysis

Key Uncertainties

Execution risk of ongoing projects and potential miscalculation of market demand for new verticals like semiconductors could impact profitability by 5-10%.